12.12.25 -- New Podcast Episodes: Building An Oral Vaccine Platform, Biotech Collaboration Strategy, Treating Inherited Retinal Disorders

Check out the latest episodes from Better Biopharma, Cell & Gene: The Podcast, and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

In this episode, host Tyler Menichiello is joined by Sean Tucker, Ph.D., founder and chief scientific officer at Vaxart, a company developing oral recombinant pill vaccines.

Host Tyler Menichiello is joined by Patrick Bilbo, chief operating officer at Organogenesis, a regenerative medicine company developing and manufacturing advanced wound care products.

Here, host Tyler Menichiello is joined by Bonum Therapeutics' chief scientific officer, Diane Hollenbaugh, Ph.D., and chief business officer, Neela Patel, Ph.D.

On this episode, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder.

Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. 

Allan Shaw, Chief Financial Officer and Chief Business Officer at CREATE Medicines, is back on the Business of Biotech, with a temperature check on biotech funding and the IPO market.

Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, and more.

On this episode, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3Β inhibitor for cancer.

On this episode, host Erin Harris talks to Aliya Omer, Vice President and Global Head of Hematology and Cell Therapy at AstraZeneca, who shares valuable insights from her rich experience leading cell therapy development across multiple top companies.

Host Erin Harris talks to Dr. Arun Upadhyay, Chief Scientific officer, Head of Research and Development at Ocugen to discuss how the company’s modifier gene therapy platform is redefining treatment possibilities for inherited retinal diseases such as retinitis pigmentosa, Stargardt disease, and geographic atrophy.

Here, podcast host Erin Harris welcomes Paul Perreault, Strategic Advisor, Board Member and former CEO of CSL, who shares insights from his decade leading the company through global expansion and the COVID-19 pandemic.